An innovative bio-inspired universal oxygen carrier at the heart of the battle against the Covid-19
The first universal oxygen carrier for therapeutic purposes, at the heart of the battle against Covid-19.
Press Releases : OUEST FRANCE / 27 APR 2020 / Hemarina resumes the fight against Covid-19 with a new test of its marine worm molecule FRANCE INTER / 07 APRIL 2020 / Against Covid-19, the first haemoglobin tests of the marine worm Arenicola SORBONE UNIVERSITY / 07 APR 2020 / Covid-19. A sea worm to help patients. Interview with Franck Zal, co-founder of Hemarina YAHOO NEWS / 06 APR 2020 / Lugworm Blood Offers Hope For COVID-19 Victims VARESE PRESS / 06 APR 2020 / Arenicola, the super-verme of the sea, a remedy to cure people suffering from cancer? EURONEWS / 06 APR 2020 / Corsa contro il tempo per battere il virus RMC BOURDIN DIRECT / 06 APR 2020 / Interview with Franck Zal VOA NEWS / / 06 APR 2020 / Sandworm Blood Could Help Coronavirus Victims WIRTSCHAFTS WOCHE / 05 APR 2020 / Können Wattwürmer Corona-Patienten helfen? FRANCE TV / 05 APR 2020 / France 2 8pm news (à 31:30) BFMTV / 04 APR 2020 / Green light for clinical trial with marine worm blood for Covid-19 patients AP-HP / 04 APR 2020 / The MONACO trial is evaluating the safety of a marine worm blood solution in patients with Covid-19-related acute respiratory distress syndrome THE WORLD / 04 APR 2020 / Coronavirus: a marine worm could bring a dose of oxygen to Covid-19 patients BFMTV / 03 APR 2020 / Coronavirus: how this marine worm can help hospitals FOR SCIENCE / 02 APR 2020 / A sea worm for respiratory distress VOCE CONTROCO / 01 APR 2020 / Coronavirus, l'arenicola un rimedio per guarire i malati? L'EXPRESS / 31 MAR 2020 / Coronavirus: marine worm blood could be used to treat patients PARIS MATCH / 31 MAR 2020 / Marine worm blood to treat Covid-19 patients EN24 / 30 MAR 2020 / Coronavirus: sea worm blood to treat patients with Covid-19? JOURNAL DU QUEBEC / 29 MAR 2020 / COVID-19: marine worms to the rescue? INDUSTRY GLOBAL NEWS / 28 MAR 2020 / French worm's blood: cure for Covid 19? SUD OUEST / 28 MAR 2020 / Prof. Laurent Lantieri asks to test the marine worm blood product against the coronavirus EUROPE 1 / 26 MAR 2020 / Coronavirus: can this marine worm help patients with respiratory failure? LE FIGARO / 26 MAR 2020 / Coronavirus: hope from a small marine worm LE PARISIEN / 25 MAR 2020 / Coronavirus: Breton sea worm could help patients FRANCE 3 BRETAGNE / 24 MAR 2020 / Coronavirus: will marine worm haemoglobin save lives? SCIENCEPOST / 21 MAR 2020 / Covid-19: how can this marine worm help us save lives? LA CROIX / 20 MAR 2020 / Coronavirus: a super-oxygenating molecule to save patients in intensive care? PHARMA INDUSTRY / 20 MAR 2020 / Covid-19: Hemarina offers its oxygen-carrying molecule LES ECHOS / 19 MAR 2020 / Hemarina proposes its marine worm molecule to treat Covid-19 L'OBS / 19 MAR 2020 / Professor Lantieri's call to use marine worm blood against Covid-19 CORELIS / 19 MAR 2020 / Coronavirus: a marine worm to help patients breathe LE JOURNAL DES ENTREPRISES / 18 MAR 2020 / Franck Zal (Hemarina): "By replacing artificial respirators, our molecule can save lives LE TELEGRAMME / 18 MAR 2020 / "We could cure 5,000 people": Hemarina's marine worm, hope for the coronavirus? LINKEDIN FRANCK ZAL / 15 MAR 2020 / HEMARINA ready to make its technology platform available to health authorities to fight the most serious syndromes of Covid-19
Presentation:
The Hemarina technology platform is based on the particularities of the purified haemoglobin of areca worms, Arenicola marina. Its structure is comparable to that of human haemoglobin, but it differs in :
- its extra-cellular nature (it is not contained in a red blood cell), and therefore universal (compatible with all blood types)
- its ability to bind 40 times more oxygen than human haemoglobin
- its particularly small size: 250 times smaller that the human red blood cell
Hemarina is a biopharmaceutical laboratory specialises in the development of health products based on its proprietary technology platform (M101), which is based on the haemoglobin properties of the arenicolous marine worm. A spin-off of the CNRS and Sorbonne University (Paris VI), Hemarina was created in 2007 in the North Finistère region of France.
Convinced of the potential of the natural biopolymer resulting from 450 million years of evolution as an innovative therapeutic option to address pathologies for which there are significant unmet medical needs today, Franck Zal decided to create his company based on fifteen years of fundamental research.
Major innovation compared to all other HBOCs (Hemoglobin-Based Oxygen Carrier) that have been developed to date, Hemarina's technology, unique in the world, is based on the only naturally extracellular high molecular weight haemoglobin, operating over a wide temperature range (4°C to 37°C) and requiring no cofactor to release oxygen.
Furthermore, one of the key advantages of this technology is the absence of vasoconstrictive and hypertensive effects as observed with first and second generation HBOCs manufactured from animal (bovine or porcine) or human haemoglobin.
Videos :
Franck Zal's speech at Biomim'expo 2016 (first edition) :
The board Biomim'review :
Sources / contacts :
Hemarina SA
Aeropole centre
29600 MORLAIX
Tel: +33 (0)2 98 88 14 02
Franck Zal on LinkedIn
Hemarina on Twitter
Pingback: MARINE & OCEANS | Biomim'expo